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Abstract 
The synthesis of the two fluorinated tricyclic nucleosides 6’F-tc-T and 6’F-tc-5MeC, as well as the 
corresponding building blocks for oligonucleotide assembly was accomplished. An X-ray 
analysis of N4-benzoylated 6’F-tc-5MeC reavealed a 2’-exo (North) conformation of the furanose 
ring characterizing it as an RNA mimic. In contrast to observations in the bicyclo-DNA series, no 
short contact between the fluorine atom and the H6 of the base, reminiscent of a non-classical 
F…H hydrogen bond, could be observed. Tm measurements of modified oligodeoxynucleotides 
with complementary RNA showed slightly sequence dependent duplex stabilization profiles with 
maximum Tm/mod values of +4.5°C for 6’F-tc-5MeC and +1°C for 6’F-tc-T. In comparison with 
parent tc-modified oligonucleotides, no relevant changes in Tm were detected, attributing the 
fluorine substituent a neutral role in RNA affinity. A structural analysis of duplexes with DNA 
and RNA by CD-spectroscopy revealed a shift from B- to A-type conformation induced by the 
6’F-tc-nucleosides. This is not a specific ‘fluorine effect’ as the same is also observed for the 
parent tc-modifications. The two fluorinated tc-nucleosides were also incorporated into a pure 
tricyclo-DNA backbone and showed no discrimination in Tm with complementary RNA, 
demonstrating that 6’F substitution is also compatible within fully modified tc-oligonucleotides.  
 
Introduction 
Fluorine is widely appreciated in small molecule medicinal chemistry due its metabolic stability 
enhancing properties and its unique protein binding characteristics.1-3 For similar reasons 
fluorinated DNA analogues are of interest in oligonucleotide therapeutic approaches. Amongst 
the first fluorinated oligonucleotides investigated were the 2’-deoxy-2’-fluoro RNA (F-RNA) and 
the 2’deoxy-2’-fluoro-arabino nucleic acids (F-ANA, Figure 1). While both analogues are known 
for quite some time, their structural and biophysical features have only recently been 
characterized in detail. Compared to their 2’-hydroxy variants RNA and ANA, both the F-RNA 
and F-ANA analogues bind with higher affinity (Tm = 1-2°C/mod) to complementary RNA. The 
origin of the higher duplex stability in the case of F-RNA was attributed to improved hydrogen-
bonding and base-stacking as a consequence of the polar C2’-F bond.4,5 In the case of F-ANA, 
internucleoside F-H8 pseudo hydrogen-bonds, that are particularly strong at purine/pyrimidine 
sequence steps, have been invoked as stability enhancing feature.6,7 F-RNA and F-ANA have 
been shown to improve the performance of therapeutic siRNAs.8,9 Due to its unique RNaseH 
activating properties, F-ANA was also investigated in classical antisense applications.10 
Recently there has been a growing interest in investigating the effect of fluorine substitution in 
more complex, carbohydrate modified oligonucleotide analogs such as F-HNA and its 2’-epimer 
Ara-F-HNA.11,12 While F-HNA shows increased thermal stability (Tm = +2 °C/mod) in complex 
with complementary RNA, the F-Ara-HNA analogue exhibits the opposite effect (Tm = -3 
°C/mod). The destabilization of Ara-F-HNA was attributed to repulsive steric effects of the 
fluoro substituent onto the 5’-adjacent nucleotide unit.11 Also fluorinated versions of CeNA13 and 
cLNA14 were investigated. In these cases fluorine substitution does not contribute significantly to 
duplex stability. The most recent additions to the palette of fluorinated oligonucleotide analogues 
were F-NMC and Ara-F-NMC,15 both derived from the northern methanocarbacyclic nucleoside 
(NMC) analogues.16,17 Here again, F-NMC stabilized duplexes by +2.2°C/mod on average while 
Ara-F-NMC was destabilizing by -2.8°C/mod. The intrinsic contribution of the fluorine atom to 
thermal stability in the case of F-NMC was determined to be +0.6°C/mod on average.18 
 
FIGURE 1: Chemical Structures of selected fluorinated nucleic acid analogues 
 
In terms of biological activity it has been shown previously that F-HNA gapmers can down-
regulate gene expression in vivo in liver tissue more potently than LNA despite lower target 
affinity.11 Thus, the higher potency of F-HNA seems to be the consequence of either improved 
biostability or more efficient plasma transport or both. Other recent observations, attributing a 
special but yet elusive role to fluorine in antisense efficacy were reported for gapmer 
oligonucleotides with F-RNA or F-ANA units targeting mutant huntingtin,19 and for F-RNA 
antisense oligonucleotides recruiting the interleukin enhancer-binding factor complex (ILF2/3).20 
Given these intriguing properties of fluorinated oligonucleotides, and building on earlier work on 
6’F-bicyclo-DNA,21 we decided to investigate 6’F-tc-DNA (Figure 1). In the following we 
present the synthesis and structural properties of the corresponding 6’F-tc-nucleosides containing 
the bases thymine and 5-methyl cytosine, as well as the influence on duplex stability and 
conformation of these modifications if complexed with complementary RNA and DNA. 
 
Results and Discussion 
Synthesis of the phosphoramidite building blocks 11 and 18. Drawing on earlier experiences 
during the synthesis of 6’-fluorinated bicyclo-DNA21 we envisaged to introduce the fluorine atom 
in an early step of the synthesis via electrophilic fluorination of a metalated bicyclic sugar 
intermediate. Consequently we started our synthetic journey with the known bicyclic silylenol 
ether 1 (Scheme 1).22 Bromination of 1 with Br2 at -78 °C gave the expected bromide 2 in 90% 
yield. To exclude side reactions during the following metal-halogen exchange, the free OH group 
in 2 was protected as a TMS ether (→ 3). Electrophilic fluorination of 3 worked best if t-BuLi 
was used as lithiation reagent and if NFSI was added in one portion at a temperature of -120 °C. 
Temperatures above -78°C, or addition of NFSI in multiple portions, lead to substantial 
decomposition and thus reduced yield. The treatment with an acidic ion exchange resin after 
quenching of the reaction quantitatively removed the TMS group, resulting in a 60% yield of 
fluorosilylenol ether 4. The rationale of removing the TMS group at this stage was based on the 
hypothesis that the corresponding hydroxyl group could help in directing the subsequent 
cyclopropanation reaction to the convex side of the bicyclic ring system. Indeed, 
cyclopropanation of 4 with a Zn-carbene complex in homogeneous solution yielded exclusively 
the exo-tricyclic sugar 5 in good yield, but only if TFA was added as accelerator.23 To prepare for 
-selective nucleosidation,24,25 compound 5 was converted to enolether 6 with TMSOTf, which 
was then reacted with in situ persilylated thymine and NIS, yielding iodo-nucleoside 7 in 85% 
yield in a stereospecific manner. Removal of the iodine via radical reduction with Bu3SnH finally 
gave the expected O-protected 6’-fluoro tricyclothymidine 8 in excellent yields. From here the 
synthesis of the phosphoramidite building block was completed by standard removal of the silyl 
protecting groups (→ 9) followed by dimethoxytritylation (→ 10) and phosphitylation with 2-
cyanoethyl diisopropyamino chlorophosphine (CEP-Cl) to give 11 in a respectable overall yield 
of 13.4% starting from 1. 
 
SCHEME 1. Synthesis of phosphoramidite 11 
 
Given the availability of the thymine nucleoside 8 and known procedures to interconvert 
pyrimidine bases on the level of nucleosides and oligonucleotides,26,27 we next envisioned the 
synthesis of the building block 18 containing the base 5-methyl cytosine. To this end compound 8 
was transformed into the triazolide 12 with 1,2,4-triazole and POCl3. Treatment of 12 with 
ammonia then afforded the 5-methly tricyclocytidine 13 in 60% yield over two steps. N4-
Benzoylation of 13 with Bz2O yielded the two nucleosides 14 and 15 that differed only by the 
presence or absence of the 3’-O-TMS group. This was of no harm as the silyl groups in both, 14 
and 15 were removed in the next step, yielding 16 in high yield. The synthesis of the 
phosphoramidite building block 18 was then completed via standard dimethoxytritylation (→ 17) 
followed by phosphitylation as described above. 
 
SCHEME 2. Synthesis of phosphoramidite 18  
X-ray structure of 16. To confirm the relative configuration and to determine the effect of the 
fluorine substituent on the conformation of the tricyclic ring system, crystals of nucleoside 16 
were grown and subjected to X-ray analysis. The molecular structure is depicted in Figure 2.
       
FIGURE 2. Ortep plot (50% probability ellipsoids) of the X-ray structure of nucleoside 16: top-
view (left) and side-view (right). Non relevant hydrogen atoms as well as the N4-benzoyl residue 
in 16 are omitted for clarity. 
 
The furanose unit in 16 adopts a 2’-exo conformation with a pseudorotation phase angle P of 
336° and a maximum torsion angle max of 31°. It thus belongs clearly to the N-type 
conformation, typically adopted by RNA nucleosides.28 The base is oriented in the central anti-
range ( = -176.2 °). Comparison of 16 with the structure of 6’-fluoro-bicyclo-T 21 reveals two 
major differences: First, the distance F-H6 in 16 (3.194 Å) is too long for a non-classical F-H 
hydrogen bond while the same distance in 6’-fluoro-bc-T (2.865 Å) is indicative for such a weak 
interaction. Furthermore, there is no linear arrangement of F-H6-C6 in 16, whereas this is clearly 
the case in 6’fluoro-bc-T. Support for the absence of such an interaction in 16 comes also from 
the fact that there are no F-H6 or F-C6 couplings observable in the 1H- and 13C-NMR spectra of 
16, which contrasts the findings in the case of 6’fluoro-bc-T. Thus, compared to 6’fluoro-bc-T, 
the base orienting H-F interaction of the fluorine is lost in 16. The second structural change 
resides within the furanose conformation, which is 1’-exo (S-type) in the case of 6’-
fluorobicyclo-T and 2’-exo (N-type) in the case of 16. With respect to the non-fluorinated 
tricyclo-T nucleoside which coexists in a 2’-endo (S-type) and a 4’-endo (E-type) conformation 
in the crystal,29 it could well be that the fluoro atom helps to drive the furanose conformation of 
the tricyclic scaffold into a N-type conformation. We cannot exclude, however, that the higher 
propensity of N-conformation in 16 is also simply an effect of the base 5-methyl cytosine. 
Unfortunately, there are currently no X-ray structures for the non-fluorinated tc-C or tc-5MeC 
nucleosides available. 
Synthesis of oligonucleotides and Tm-data. Oligodeoxynucleotides ON1-10, containing the 
6’fluoro-tc-nucleosides, (Table 1) were synthesized on the 1.3 mol scale by standard 
phosphoramidite chemistry, utilizing the building blocks 11 and 18 (for details see experimental 
section). Crude oligonucleotides were deprotected and detached from solid support by standard 
ammonia treatment (33% NH4OH, 55°C, overnight) and purified by ion exchange HPLC. The 
composition of all oligonucleotides was verified by ESI- mass spectrometry (Tables 1 and 3).  
  
Table 1. Analytical data of oligodeoxynucleotides ON1-ON7, containing 6’fluoro-tc-T (t) or 
6’fluoro-tc-5MeC (c) units, as well as Tm-data of duplexes with complementary DNA and RNA.  
 Sequence 
ESI–MS 
m/z calc 
ESI–MS 
m/z found 
Tm (°C) vs DNA
a,b 
(∆Tm/mod) 
Tm (°C) vs RNA
a,c 
(∆Tm/mod) 
ON1 d(AACTGtCACG) 3067.6 3067.5 45.5 (+2.0) 44.4 (0.0) 
ON2 d(AACtGTCACG) 3067.6 3067.5 45.1 (+1.6) 45.4 (+1.0) 
ON3 d(AACtGtCACG)  3123.6 3123.5 43.5 (0.0) 44.3 (0.0) 
ON4 d(GCAtttttACCG) 3890.7 3890.6 43.1 (-0.6)d 45.6 (+0.5)e 
ON5 d(AACTGTcACG) 3081.6 3081.5 44.6 (+1.1) 46.3 (+1.9) 
ON6 d(AAcTGTCACG)  3081.6 3081.5 44.9 (+1.4) 48.9(+4.5) 
ON7 d(AAcTGTcACG) 3151.6 3151.6 48.2 (+2.4) 51.0 (+3.3) 
a Total strand conc: 2 μM in 10 mM NaH2PO4, 150 mM NaCl, pH 7.0. Estimated error in Tm = 
±0.5°C. b Tm of unmodified duplex: 43.5°C. 
c Tm of unmodified duplex: 44.4°C. 
d Tm of 
unmodified duplex: 46.3°C. e Tm of unmodified duplex: 42.9°C 
 
Oligodeoxynucleotides containing single 6’fluoro tc-T mutations (ON1-3) lead to duplexes with 
complementary DNA and RNA with neutral to slightly enhanced stability in a slightly sequence 
dependent context, compared to unmodified duplexes. Interestingly, the stabilization (Tm/mod.) 
is a bit stronger in duplexes with complementary DNA as compared to RNA. Double 
substitutions in a non-contiguous order (ON3) tendentially lead to poorer duplex stabilization 
with RNA compared to multiple substitutions in a consecutive manner (ON4). This is in 
agreement with earlier observations in the series of tc-DNA,30 and has been ascribed to an 
incremental energetic penalty arising from increasing numbers of structural hetrobackbone 
junctions. Replacing natural dC with 6’fluoro-tc-5MeC units (ON5-7) leads to a somewhat 
different picture. Again, in a slightly sequence dependent context, duplex stabilization is 
significantly higher (up to +4.5 °C/mod) as compared to dC and more pronounced with RNA as a 
complement. In addition, there seems to be almost no energetic penalty as a function of the 
number of non-contiguous substitutions (ON5 and ON6 vs ON7). While it is known that the base 
thymine in the tc-DNA context is least stabilizing compared to the other three bases,30,31 the 
origin of this effect is yet unknown and awaits further structural investigations.  
To elucidate the role of the fluorine atom and the methyl group in 5-methyl cytosine on RNA 
duplex stability we compared Tm/mod data with that of oligonucleotides containing tc-T, tc-C 
and tc-5MeC residues, resp. (Table 2). From this set of data it becomes evident that in both the T- 
and C-series, the 6’-fluorine atom behaves neutral and does not significantly add to duplex 
stability. This is in agreement with the absence of any F-H5 pseudo-hydrogen bond, as found in 
the X-ray structure of 16, and supports our earlier hypothesis that this interaction is responsible 
for the increase in stability in the bc-DNA series.21 At the same time it is in agreement with the 
properties of other 6’-modified tc-DNA derivatives for which it was shown before that this 
position can be chemically modified without compromising RNA affinity.24 In the C-series, the 
5-methyl group of cytosine brings about 0.2-1.2 °C/mod of additional thermal stability also in the 
context of the tricyclic nucleoside structure. As for the case of 5-methyldeoxycytidine in DNA 
duplexes, this is most likely the consequence of improved stacking interactions and/or improved 
hydrogen bonding induced by the molecular polarizability of the size extended base.32  
 
Table 2. Structure affinity relationship: Tm/mod data for oligodeoxynucleotides containing 
parent or substituted tc-nucleosides in complex with complementary RNA.  
X tc-T 6’F-tc-T  tc-C tc-5MeC 6’F-tc-5MeC 
d(AACTGXCACG) -0.1 0.0 d(AACTGTXACG) +2.0 +2.2 +1.9 
d(AACXGTCACG) +1.4 +1.0 d(AAXTGTCACG) +3.0 +4.2 +4.5 
d(AACXGXCACG) +0.4 0.0 d(AAXTGTXACG) +2.5 +3.6 +3.3 
Experimental conditions as in Table1. 
In the context of future applications as steric block or splice switching oligonucleotides we 
investigated also the fully modified tc-oligonucleotides ON8-10 containing 6’-fluoro-tc-T units. 
These oligonucleotides all carry a 5’-phosphate unit in order to confer chemical stability to the 
5’-terminal nucleoside unit during oligonucleotide deprotection.33 As can be seen from Table 3, 
duplexes with complementary DNA (non 5’-phosphorylated) are somewhat destabilized in the 
presence of the fluorine atom, while a slight stabilization in a sequence dependent manner occurs 
with RNA (non 5’-phosphorylated) as complement. Thus 6’-fluorination is fully compatible with 
the tc-DNA backbone and does not lead to loss of RNA affinity. 
 
Table 3. Analytical data of tc-oligonucleotides ON8-ON10, containing 6’-fluoro-tc-T (t), and 
Tm-data of duplexes with complementary DNA and RNA. 
 Sequencea 
ESI–MS 
m/z calc 
ESI–MS 
m/z found 
Tm (°C) vs DNA
b,c 
(∆Tm/mod) 
Tm (°C) vs RNA
b,d 
(∆Tm/mod) 
ON8 d(pAACTGtCACG) 3490.5 3489.6 55.0 (0.0) 68.0 (+1.6) 
ON9 d(pAACtGTCACG) 3490.5 3489.6 53.4 (-1.6) 66.7 (+0.3) 
ON10 d(pAACtGtCACG)  3508.5 3507.6 53.2 (-1.8) 66.3 (-0.1) 
a Characters in italic denote regular tc-DNA residues, p denotes a 5’-phosphate group. b Total 
strand conc: 2 μM in 10 mM NaH2PO4, 150 mM NaCl, pH 7.0. Estimated error in Tm = ±0.5°C. c 
Tm of unmodified duplex: 55.0°C. 
d Tm of unmodified duplex: 66.4°C 
 
To determine the effect of 6’F-tc-T units on duplex conformation we measured CD spectra of 
duplexes of ON4 with complementary DNA and RNA and compared them with the 
corresponding unmodified duplexes and with duplexes containing tc-T instead of 6’F-tc-T units 
(Figure 3). The largest structural deviation occurs in the DNA/DNA duplex series where both, the 
6’F-tc-T and the tc-T units drive the duplex conformation from B to A-like. There are no 
significant differences between duplexes with tc-T or 6’fluoro-tc-T, indicating that both adopt an 
N-type nucleoside conformation. The tendency to adopt a more A-like conformation in duplexes 
with tc-T or 6’F-tc-T units is also present in the DNA/RNA duplex series. Again, there are no 
large differences between the tc-T and 6’F-tc-T containing duplexes, perhaps with the exception 
that the maximum positive ellipticity around 270 nm is blue shifted by ca 10 nm in the case of the 
latter duplex, with a yet unknown implication on the helix structure. 
 
FIGURE 3. CD-spectra of left: DNA/RNA duplexes and right: DNA/DNA duplexes. Black lines: 
unmodified duplexes, red lines duplexes with ON4, and blue lines duplexes with ON4 in which 
6’-fluoro-tc-T was replaced by tc-T. Experimental conditions as indicated in Table 1. 
 
Conclusion: 
We have accomplished the synthesis of the two 6’fluorinated tc-nucleoside building blocks 11 
and 18 and have incorporated them into oligodeoxynucleotides and tc-oligonucleotides. We 
analyzed complementary DNA and RNA affinity by Tm-measurements and determined structural 
effects of fluorine substitution on duplex conformation by CD spectroscopy. Based on the X-ray 
structure of 16 as well as on 1H- and 13C-NMR coupling data on the nucleosides and derivatives 
we could not find any indications for short fluorine-base F-H6 contacts. This is in surprising 
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contrast to findings in the 6’-fluoro-bc-DNA series, where such short contacts were observed. 
Compared to the non-fluorinated tc-nucleosides we find that the fluorine substituent does not 
significantly alter the thermal melting properties of the corresponding duplexes, irrespective of 
the nature of the base (thymine vs 5-methylcytosine). This is in agreement with the absence of the 
glycosidic bond constraining nature of the F-H6 interaction that adds up to +2°C/mod in Tm in the 
case of the bicyclo-DNA series. The 6’-fluoro modification is also compatible with the tc-DNA 
backbone as no change or even a slight increase in Tm with complementary RNA was observed. 
The fluorine atom does also not significantly alter the duplex conformation compared to non-
fluorinated tc-DNA as can be seen from the corresponding CD-spectra. Based on these 
encouraging biophysical data we are now planning to investigate functional efficacy, cellular 
uptake and in vivo tissue distribution of antisense tc-oligonucleotides containing these 6’F-tc-
nucleosides. 
 
Experimental Section 
General Methods. All reactions were performed under argon in oven dried glassware. Solvents 
were dried by filtration over activated alumina or by storage over molecular sieves (4 Å). Column 
chromatography (CC) was performed on silica gel 60 (230-400 mesh, neutralized with 0.1% of 
w/Ca). All solvents for CC were of technical grade and distilled prior to use. Thin-layer 
chromatography (TLC) was performed on silica gel plates. Compounds were visualized either 
under UV light or by staining in dip solution A: CerIV-sulfate (10.5 g), phosphormolybdenic acid 
(21 g), conc. H2SO4 (60 mL), H2O (900 mL); or B: KMnO4 (6 g), K2CO3 (40 g), 15% NaOH (3 
mL) in H2O (800 mL)), followed by heating with a heat gun. NMR spectra were recorded at 300 
or 400 MHz (1H), at 75MHz or 100MHz (13C), at 376 MHz (19F) and at 162 MHz (31P). Chemical 
shifts (δ) are reported relative to the undeuterated residual solvent peak (CHCl3: 7.24 ppm (1H) 
and 77.2 ppm (13C); DMSO-d6: 2.50 ppm (1H) and 39.5 ppm (13C)). Signal assignments are 
based on DEPT or APT experiments, and on 1H,1H- and 1H,13C-correlation experiments (COSY, 
HSQC). 13C signal multiplicities include 1H- and 19F-couplings.  1H-NMR difference-NOESY 
experiments were recorded at 400 MHz. Chemical shifts for 31P and 19F NMR (fully proton 
coupled) are reported relative to 85% H3PO4 and CFCl3 as external standards, respectively. 
Electrospray ionization in the positive mode (ion trap, ESI+) was used for high resolution mass 
detection. The numbering scheme for tc-nucleosides is outlined in Figure 1. For non-nucleoside 
derivatives the von Baeyer nomenclature has been applied. 
(1S,3R,5S)-7-Bromo-8-tert-butyldimethylsilyloxy-3-methoxy-2-oxabicyclo[3.3.0]oct-7-en-5-
ol (2). To a stirred solution of silylenolether 1 (10.6 g, 37.0 mmol) in dry CH2Cl2 (100 mL) was 
added dropwise a solution of bromine (2.1 mL, 40.7 mmol) in CH2Cl2 (200 mL) over a period of 
30 min at -78°C, followed by Et3N (7.7 mL, 55.48 mmol). The cooling bath was subsequently 
removed and the temperature was allowed to rise to rt. Stirring was continued for another 2 h. 
Then the reaction mixture was poured into H2O and extracted with Et2O. The combined organic 
layers were washed with water, dried over MgSO4 and evaporated. The residual dark oil was 
purified by CC (hexane/EtOAc 4:1) to give the title compound 2 (12.1 g, 90%) as a yellow oil. 
Data for 2. Rf = 0.33 (hexane/EtOAc 7:3); 1H NMR (CDCl3, 300 MHz) δ 5.04 (d, J = 4.1 Hz, 1H, 
H-C(3)), 4.57 (m, 1H, H-C(1)), 3.37 (s, 3H, OMe), 3.15 (s, 1H, OH), 2.76 (d, J = 15.3 Hz, 1H, 
Hb-C(6)), 2.67 (dd, J = 2.2, 15.3 Hz, 1H, Ha-C(6)), 2.25 (d, J = 13.5 Hz, 1H, Hb-C(4)), 2.02 (dd, J 
= 4.1, 13.5 Hz, 1H, Ha-C(4)), 0.97 (s, 9H, t-Bu), 0.24, 0.20 (2s, 2x3H, 2xCH3); 
13C NMR (CDCl3, 
75 MHz) δ 148.4 (s, C(8)), 105.3 (d, C(3)), 96.7 (s, C(7)), 90.4 (d, C(1)), 83.4 (s, C(5)), 54.7 (q, 
OMe), 47.2 (t, C(6)), 44.8 (t, C(4)), 25.8 (q, t-Bu), 18.4 (s, t-Bu), -3.9, -4.2 (2xs, 2xCH3); ESI
+-
HRMS m/z calcd for C14H25BrNaO4Si [M+Na]
+ 387.0603, 389.0583, found 387.0598, 389.0577. 
 (1S,3R,5S)-7-Bromo-8-tert-butyldimethylsilyloxy-3-methoxy-5-trimethylsilyloxy-2-
oxabicyclo[3.3.0]oct-7-en (3). To a stirred solution of bromosilylenolether 2 (12.0 g, 32.74 
mmol) in dry pyridine (170 mL) was added BSA (12 mL, 49.11 mmol) at rt and the mixture left 
overnight. The reaction mixture was diluted with sat aq NaHCO3 and extracted with Et2O. The 
combined organic layers were dried over MgSO4, evaporated and the residual oil purified by CC 
(hexane/EtOAc 95:5, with 0.5% of Et3N) to yield the title compound 3 (13.0 g, 91%) s a yellow 
oil. 
Data for 3. Rf = 0.68 (hexane/EtOAc 9:1); 1H NMR (CDCl3, 300 MHz) δ 4.99 (dd, J = 1.3, 5.3 
Hz, 1H, H-C(3)), 4.64 (t, J = 1.4 Hz, 1H, H-C(1)), 3.35 (s, 3H, OMe), 2.73 (d, J = 1.5 Hz, 2H, H-
C(6)), 2.33 (dd, J = 1.3, 13.7 Hz, 1H, Hb-C(4)), 2.06 (dd, J = 5.3, 13.7 Hz, 1H, Ha-C(4)), 0.97 (s, 
9H, t-Bu), 0.24, 0.21 (2s, 2x3H, 2xCH3), 0.15 (s, 9H, TMS); 
13C NMR (CDCl3, 75 MHz) δ 148.6 
(s, C(8)), 105.7 (d, C(3)), 96.4 (s, C(7)), 90.3 (d, C(1)), 84.8 (s, C(5)), 55.2 (q, OMe), 49.5 (t, 
C(6)), 48.4 (t, C(4)), 25.8 (q, t-Bu), 18.4 (s, t-Bu), 1.9 (q, TMS), -3.9, -4.2 (2q, 2xCH3); ESI
+-
HRMS m/z  calcd for C17H33BrNaO4Si2 [M+Na]
+ 459.0998, 461.0978, found 459.1002, 
461.0981. 
 
(1S,3R,5S)-7-Fluoro-8-tert-butyldimethylsilyloxy-3-methoxy-2-oxabicyclo[3.3.0]oct-7-en-5-ol 
(4). To a stirred solution of bromosilylenolether 3 (6.14 g, 14.04 mmol) in dry THF (211 mL) and 
ether (42 mL) was added dropwise a solution of t-BuLi (1.7 M in pentane, 16.5 mL, 28.08 mmol) 
at -78°C. After stirring for 20 min the reaction mixture was further cooled to -120°C and NFSI 
(8.85 g, 28.08 mmol) was added at once, followed by another portion of t-BuLi (24.8 mL, 42.12 
mmol). The reaction mixture was stirred for 2 hours and then allowed to warm up to -80°C. After 
quenching with water (210 mL) the mixture was warmed up to rt and extracted with EtOAc. The 
combined organic phases were dried over MgSO4 and evaporated. The residue was then 
dissolved in dry ether (200 mL), treated with amberlyst 15 (6.1 g) and the mixture stirred for 2 
hours at rt. The amberlyst was then filtered off and SiO2 was added to the filtrate prior to 
evaporation. Purification by CC (CH2Cl2/hexane 7:3 → CH2Cl2, + 1% Et2O) gave the title 
comound 4 (2.56 g, 60 %) in form of a yellowish solid. 
Data for 4. Rf = 0.53 (hexane/EtOAc 3:1); 
1H NMR (CDCl3, 300 MHz) δ 5.05 (d, J = 4.1 Hz, 1H, 
H-C(3)), 4.58 (dt, J = 1.8, 8.0 Hz, 1H, H-C(1)), 3.38 (s, 3H, OMe), 3.11 (d, J = 2.3 Hz, 1H, OH), 
2.62 (m, 2H, H-C(6)), 2.28 (d, J = 13.4 Hz, 1H, Hb-C(4)), 1.97 (dd, J = 4.1, 13.4 Hz, 1H, Ha-
C(4)), 0.95 (s, 9H, t-Bu), 0.19, 0.17 (2s, 2x3H, 2xCH3); 
13C NMR (CDCl3, 75 MHz) δ 138.5 (d, J 
(C,F) = 272.2 Hz, C(7)), 128.6 (d, J (C,F) = 4.0 Hz, C(8)), 104.8 (d, C(3)), 89.9 (dd, J (C,F) = 
5.3 Hz, C(1)), 79.7 (d, J (C,F) = 11.6 Hz, C(5)), 54.7 (q, OMe), 47.5 (t, C(4)), 37.4 (td, J (C,F) = 
18.6 Hz, C(6)), 25.7 (q, t-Bu), 18.3 (s, t-Bu), -4.3 (qd, J = 1.7 Hz), CH3), -4.56 (qd, J = 2.1 Hz, 
CH3); 
19F NMR (CDCl3, 376 MHz) δ -138.5 (s, br); ESI+-HRMS m/z calcd for C14H25FNaO4Si 
[M+Na]+ 327.1404, found 327.1412. 
 
(1S,2S,4S,6R,8S)-2-tert-Butyldimethylsilyloxy-4-fluoro-8-methoxy-9-
oxatricyclo[4.3.01.6.02.4]nonane-6-ol (5). To dry CH2Cl2 (97 mL) was added a solution of Et2Zn 
(1 M in hexane, 48.2 mL 48.20 mmol). The mixture was cooled to 0°C and a solution of TFA 
(3.69 mL, 48.21 mmol) in CH2Cl2 (48 mL) was slowly added. After stirring for 20 min a solution 
of CH2I2 (7.76 mL, 96.42 mmol) in CH2Cl2 (48 mL) was added. After another 20 min of stirring, 
a solution of fluorosilylenolether 4 (2.45 g, 8.04 mmol) in CH2Cl2 (48 mL) was added, and the 
ice bath was removed. After 5 hours of stirring, the reaction mixture was quenched with sat aq 
NH4Cl and the layers separated. The aqueous layer was extracted with CH2Cl2. The combined 
organic layers were washed with sat NaHCO3, dried over MgSO4, concentrated, and purified by 
CC (hexane/EtOAc, 9:1) to yield the title compound 5 (1.79 g, 70%) as a colorless oil. 
Data for 5. Rf = 0.33 (hexane/EtOAc 3:1); 
1H NMR (CDCl3, 300 MHz) δ 5.10 (dd, J = 1.6, 5.2 
Hz, 1H, H-C(8)), 3.89 (d, J = 6.0 Hz, 1H, H-C(1)), 3.37 (s, 3H, OMe), 2.49 (m, 1H, Hb-C(5)), 
2.43 (dd, J = 5.3, 14.0 Hz, 1H, Hb-C(7)), 2.29 (dd, J = 1.1 Hz, J = 13.4 Hz, 1H, Ha-C(5)), 2.10 (s, 
br, 1H, OH), 2.06 (dd, J = 1.6, 14.0 Hz, 1H, Ha-C(7)), 1.33 (ddd, J = 2.5, 7.5, 21.5 Hz, 1H, Hb-
C(3)), 1.19 (dd, J = 7.5, 8.5 Hz, 1H, Ha-(3)), 0.91 (s, 9H, t-Bu), 0.17 (s, 6H, 2xCH3); 
13C NMR 
(CDCl3, 75 MHz) δ 105.7 (d, C(8)), 88.7 (dd, J (C,F) = 3.8 Hz, C(1)), 83.2 (d, J (C,F) = 268.2 
Hz, C(4)), 82.1 (d, J (C,F) = 5.5 Hz, C(6)), 63.7 (d, J (C,F) = 8.3 Hz, C(2)), 54.9 (q, OMe), 49.9 
(t, C(7)), 44.4 (td, J (C,F) = 16.5 Hz, C(5)), 25.9 (q, t-Bu), 21.7 (td, J (C,F) = 10.3 Hz, C(3)), 
18.3 (s, t-Bu), -3.9 (q, CH3), -4.0 (qd, J (C,F) = 1.8 Hz, CH3); 
19F NMR (CDCl3, 376 MHz) δ -
194.9 (m); ESI+-HRMS m/z calcd for C15H27FNaO4Si [M+Na]
+ 341.1560, found 341.1561. 
 
(1S,2S,4S,6R)-2-tert-Butyldimethylsilyloxy-4-fluoro-6-trimethylsilyloxy-9-
oxatricyclo[4.3.01.6.02.4]non-7-ene (6). To a solution of compound 5 (1.51 g, 4.38 mmol) and 
2,6-lutidine (2.80 mL, 24.20 mmol) in dry CH2Cl2 (10 mL) was added TMSOTf (2.14 mL, 11.84 
mmol) dropwise at 0°C. After stirring for 2.5 h at rt, the reaction mixture was diluted with 
AcOEt, washed with saturated NaHCO3 and the aqueous phase extracted with AcOEt. The 
combined organic phases were dried over MgSO4, evaporated and the residue purified by CC 
(hexane/Et2O 95:5) to give the title compound 6 (1.43 g, 91%) as light brownish oil. 
Data for 6. Rf = 0.83 (hexane/EtOAc 4:1); 1H NMR (CDCl3, 300 MHz) δ 6.33 (d, J = 2.7 Hz, 1H, 
H-C(8)), 5.15 (d, J = 2.7 Hz, 1H, H-C(7)), 4.24 (d, J = 6.0 Hz, 1H, H-C(1)), 2.52 (ddd, J = 2.8, 
11.6, 12.9 Hz, 1H, Hb-C(5)), 2.37 (dd, J = 1.1, 12.9 Hz, 1H, Ha-C(5)), 1.45 (ddd, J = 2.8, 7.4, 
10.1 Hz, 1H, Hb-C(3)), 1.02 (dd, J = 7.4, 8.4 Hz, 1H, Ha-C(3)), 0.90 (s, 9H, t-Bu), 0.15, 0.11 (2s, 
2x3H, 2xCH3), 0.09 (s, 9H, TMS); 
13C NMR (CDCl3, 75 MHz) δ 146.7 (d, C(8)), 108.4 (d, C(7)), 
94.1 (dd, J (C,F) = 4.1 Hz, C(1)), 87.1 (d, J (C,F) = 14.2 Hz, C(6)), 84.4 (d, J (C,F) = 250.2 Hz, 
C-(4)), 64.8 (d, J (C,F) = 8.4 Hz, C(2)), 48.7 (td, J (C,F) = 14.4 Hz, C(5)), 26.0 (q, t-Bu), 22.9 
(td, J (C,F) = 10.6 Hz, C(3)), 18.4 (s, t-Bu), 2.0 (q, TMS), -3.8 (q, CH3), -4.3 (qd, J (C,F) = 2.8 
Hz, CH3); 
19F NMR (CDCl3, 376 MHz) δ -192.6 (m); ESI+-HRMS m/z calcd for C17H32FO3Si2 
[M+H]+ 359.1874, found 359.1873. 
 
(5‘-O-(tert-Butyldimethylsilyl)- 3‘-O-(trimethylsilyl)-2‘-deoxy-3‘,5‘-ethano-6‘-fluoro-2‘-
iodo-5‘,6‘-methano-β-D-ribofuranosy)thymine (7). To a suspension of thymine (1.49 g, 11.80 
mmol) and compound 6 (1.41 g, 3.93 mmol) in CH2Cl2 (20 mL) was added BSA (2.88 ml, 11.80 
mmol) and the mixture was stirred at rt for 2 h to become a clear solution. Then N-
iodsuccinimide (1.32 g, 5.90 mmol) was added and the mixture stirred overnight. The reaction 
was quenched with sat NaHCO3 (30 mL) and a 10% aq solution of Na2S2O3 (10 mL). The 
aqueous phase was extracted with EtOAc and the combined organic phases were dried over 
MgSO4 and evaporated. CC (hexane/EtOAc 9:1) afforded nucleosides 7 (2,05 g, 85%) as a 
yellowish solid. 
Data for 7. Rf  = 0.39 (hexane/EtOAc 4:1); 1H NMR (CDCl3, 300 MHz) δ 9.10 (s, 1H, NH), 7.76 
(d, J = 0.9 Hz, 1H, H-C(6)), 6.38 (d, J = 2.6 Hz, 1H, H-C(1‘)), 4.56 (d, J = 2.6 Hz, 1H, H-C(2‘)), 
4.19 (d, J = 5.7 Hz, 1H, H-C(4‘)), 2.45 (d, J = 14.2 Hz, 1H, Hb-C(7‘)), 2.34 (m, 1H, Ha-C(7‘)), 
1.91 (d, J = 0.9 Hz, 3H, CH3), 1.50 (ddd, J = 2.2, 7.8, 20.9 Hz, 1H, Hb-C(8‘)), 1.19 (t, J = 8.4 Hz, 
1H, Ha-C(8‘)), 0.94 (s, 9H, t-Bu), 0.23 (s, 9H, TMS), 0.22, 0.20 (2s, 2x3H, 2xCH3); 13C NMR 
(CDCl3, 75 MHz) δ 164.3 (s, CO), 150.4 (s, CO), 135.4 (d, C(6)), 110.9 (s, C(5)), 96.8 (d, C(1‘)), 
91.2 (dd, J (C,F) = 3.7 Hz, C(4‘)), 83.9 (d, J (C,F) = 11.4 Hz, C(3‘)), 81.4 (d, J (C,F) = 250.9 Hz, 
C(6‘)), 62.7 (d, J (C,F) = 8.2 Hz, C(5‘)), 41.5 (d, C(2‘)), 41.3 (td, J (C,F) = 16.3 Hz, C(7‘)), 25.7 
(q, t-Bu), 21.7 (td, J (C,F) = 10.2 Hz, C-(8‘)), 18.0 (s, t-Bu), 12.4 (q, CH3), 2.1 (q, TMS), -3.6 (q, 
CH3), -4.0 (q, CH3); 
19F NMR (CDCl3, 376 MHz) δ -197.2 (m); ESI+-HRMS m/z calcd for 
C22H37FIN2O5Si2 [M+H]
+ 611.1270, found 611.1265. 
 
(5‘-O-(tert-Butyldimethylsilyl)- 3‘-O-(trimethylsilyl)-2‘-deoxy-3‘,5‘-ethano-6‘-fluoro-5‘,6‘-
methano-β-D-ribofuranosyl)thymine (8). To a solution of iodonucleoside 7 (2.05 g, 3.35 
mmol) in toluene (40 mL) were added Bu3SnH (1.1 mL, 4.02 mmol) and azoisobutyronitril 
(AIBN, 165 mg, 1.00 mmol) at rt. After heating to reflux for 1 h the solvent was evaporated and 
the residue purified by CC (hexane/EtOAc 8:2) to give nucleoside 8 (1,54 mg, 95%) as a 
colorless solid. 
Data for 8. Rf = 0.52 (hexane/EtOAc 1:1); 
1H NMR (CDCl3, 300 MHz) δ 8.52 (s, 1H, NH), 7.82 
(d, J = 1.0 Hz, 1H, H-C(6)), 6.03 (dd, J = 1.4, 6.4 Hz, 1H, H-C(1‘)), 4.07 (d, J = 5.6 Hz, 1H, H-
C(4‘)), 2.62 (dd, J = 6.4, 13.7 Hz, 1H, Hb-C(2‘)), 2.53 (dd, J = 1.4, 13.7 Hz, 1H, Ha-C(2‘)), 2.37 
(dd, J = 1.8, 13.7 Hz, 1H, Hb-C(7‘)), 2.13 (m, 1H, Ha-C(7‘)), 1.91 (d, J = 1.0 Hz, 3H, CH3), 1.40 
(ddd, J = 2.4, 7.7, 21.0 Hz, 1H, Hb-C(8‘)), 1.18 (dd, J = 7.7, 9.1 Hz, 1H, Ha-C(8‘)), 0.94 (s, 9H, t-
Bu), 0.23, 0.19 (2s, 2x3H, 2xCH3), 0.13 (s, 9H, TMS); 
13C NMR (CDCl3, 75 MHz) δ 164.2 (s, 
CO), 150.2 (s, CO), 136.0 (d, C(6)), 110.2 (s, C(5)), 93.0 (dd, J (C,F) = 4.0 Hz, C(4‘)), 89.6 (d, 
C(1‘)), 82.4 (d, J (C,F) = 12.3 Hz, C(3‘)), 81.43 (d, J (C,F) = 249.7 Hz, C(6‘)), 63.2 (d, J (C,F) = 
8.1 Hz, C(5‘)), 47.3 (t, C(2‘)), 44.7 (td, J (C,F) = 14.9 Hz, C(7‘)), 25.7 (q, t-Bu), 20.4 (td, J (C,F) 
= 10.0 Hz, C(8‘)), 18.0 (s, t-Bu), 12.3 (q, CH3), 2.0 (q, TMS), -3.7 (q, CH3), -3.8 (q, CH3); 19F 
NMR (CDCl3, 376 MHz) δ -197.9 (m); ESI+-HRMS m/z calcd for C22H38FN2O5Si2 [M+H]+ 
485.2303, found 485.2295. 
 
(2‘-Deoxy- 3‘,5‘-ethano-6‘-fluoro-5‘,6‘-methano-β-D-ribofuranosyl)thymine (9). To 
a solution of compound 8 (1.48 g, 3.05 mmol) and pyridine (6 mL) in CH2Cl2 (30 mL) was added 
HF-pyridine (1.5 mL, 60.6 mmol) at 0°C. After stirring overnight at rt, SiO2 (7 g) was added and 
the mixture stirred for another 15 min. After evaporation the adsorbed product was purified by 
CC (hexane/EtOAc/EtOH 5:5:1) to yield the title compound 9 (797 mg, 87%) as a white foam. 
Data for 9. Rf = 0.22 (EtOAc); 
1H NMR (CD3OD, 400 MHz) δ 7.81 (d, J = 0.9 Hz, 1H, H-C(6)), 
6.13 (dd, J = 4.0, 6.9 Hz, 1H, H-C(1‘)), 3.99 (d, J = 5.7 Hz, 1H, H-C(4‘)), 2.56 (dd, J = 6.9, 13.9 
Hz, 1H, Hb-C(2‘)), 2.45 (dd, J = 4.0, 13.9 Hz, 1H, Ha-C(2‘)), 2.38 (m, 2H, H-C(7‘)), 1.93 (d, J = 
0.9 Hz, 3H, CH3), 1.43 (ddd, J = 2.4, 7.4, 20.9 Hz, 1H, Hb-(8‘)), 1.28 (m, 1H, Ha-C(8‘)); 13C 
NMR (CD3OD, 100 MHz) δ 166.6 (s, CO), 152.1 (s, CO), 137.7 (d, C(6)), 111.0 (s, C(5)), 91.5 
(dd, J (C,F) = 3.7 Hz, C(4‘)), 89.0 (d, C(1‘)), 84.4 (d, J (C,F) = 248.0 Hz, C(6‘)), 80.9 (d, J (C,F) 
= 12.1 Hz, C(3‘)), 63.4 (d, J (C,F) = 8.4 Hz, C(5‘)), 49.0 (t, C(2‘)), 45.1 (td, J (C,F) = 15.6 Hz, 
C(7‘)), 21.1 (td, J (C,F) = 10.4 Hz, C(8‘)), 12.4 (q, CH3); 19F NMR (CD3OD, 376 MHz) δ -200.4 
(m); ESI+-HRMS m/z calcd for C13H16FN2O5 [M+H]
+ 299.1038, found 299.1037. 
 
(5‘-O-((4,4‘-Dimethoxytriphenyl)methyl)-2‘-deoxy-3‘,5‘-ethano-6‘-fluoro-5‘,6‘-methano-β-
D-ribofuranosyl)thymine (10). To a solution of nucleoside 9 (428 mg, 1.44 mmol) in pyridine 
(20 mL) was added DMTrCl (1,46 g, 4,31 mmol) at rt and the mixture was stirred for 2 days. 
Then reaction was diluted with sat. NaHCO3  and extraxted with EtOAc. The combined organic 
phasess were dried over MgSO4, evaporated and the residue purified by CC (hexane/EtOAc 8:2 
→ EtOAc, 1% Et3N) to give the title compound 10 (751 mg, 87%) as a yellowish foam. 
Data for 10. Rf = 0.38 (EtOAc); 
1H NMR (CDCl3, 400 MHz) δ 9.62 (brs, 1H, NH), 8.04 (d, J = 
0.8 Hz, 1H,H-C(6)), 7.47 (m, 2H, H-arom), 7.37 (dd, J = 8.9, 10.7 Hz, 4H, H-arom), 7.16 (m, 3H, 
H-arom), 6.75 (dd, J = 7.6, 8.9 Hz, 4H, H-arom), 5.76 (dd, J = 1.4, 6.5 Hz, 1H, H-C(1‘)), 3.70 (s, 
3H, OMe), 3.69 (s, 3H, OMe), 2.33 (dd, J = 6.5, 14.1 Hz, 1H, Hb-(2‘)), 2.23 (m, 3H, Ha-C(2‘)), 
H-C(4‘), Hb-C(7‘)), 2.09 (m, 1H, Ha-C(7‘)), 1.98 (d, J = 0.8 Hz, 3H, CH3), 1.71 (m, 1H, Hb-
C(8‘)), 0.84 (dd, J = 8.6, 9.7 Hz, 1H, Ha-C(8‘)); 13C NMR (CDCl3, 100 MHz) δ 164.7 (s, CO), 
158.95, 158.93 (2s, 2xC-arom), 150.5 (s, CO), 145.8, 136.5, 136.4 (3s, 3xC-arom), 136.3 (d, C-
6), 131.2, 131.1, 128.8, 127.8, 127.2, 113.13, 113.08 (7d, 7xC-arom), 110.3 (s, C(5)), 90.6 (dd, J 
(C,F) = 3.8 Hz, C(4‘)), 88.82 (s), 88.81 (d, C(1‘)), 83.3 (d, J (C,F) = 247.8 Hz, C(6‘)), 80.5 (d, J 
(C,F) = 12.4 Hz, C(3‘)), 64.9 (d, J (C,F) = 7.8 Hz, C(5‘)), 55.4 (q, 2xOMe), 47.9 (t, C(2‘)), 44.0 
(td, J (C,F) = 16.0 Hz, C(7‘)), 20.2 (td, J (C,F) = 9.5 Hz, C(8‘)), 12.5 (q, CH3); 19F NMR (CDCl3, 
376 MHz) δ -193.4 (m); ESI+-HRMS m/z calcd for C34H33FN2O7Na [M+Na]+ 623.2164, found 
623.2150. 
(5‘-O-(4,4‘-Dimethoxytriphenyl)methyl)-3‘-O-(2-cyanoethoxy)-
diisopropylaminophosphanyl-2‘-deoxy-3‘,5‘-ethano-6‘-fluoro-5‘,6‘-methano-β-D-
ribofuranosyl)thymine (11). To a solution of compound 10 (4.24 g, 7.06 mmol) and 
diisopropylethylamine (4.67 ml, 28.24 mmol) in CH3CN (142 mL) was added 2-cyanoethoxy-
diisopropylaminochlorophosphine (3.94 mL, 17.65 mmol) at rt. After stirring for 2 h at rt, the 
mixture was diluted with EtOAc and washed with sat aq NaHCO3. The aqueous phases were 
extracted with EtOAc and the combined organic phases were dried (MgSO4), evaporated and the 
resulting crude product purified by CC (hex/EtOAc 1:1, 1% NEt3). The purified product was 
dissolved in CH2Cl2 (10 mL), slowly added to icecold hexane (220 mL) and the precipitate 
collected. This procedure was repeated 7x to yield the pure title compound 11 (3,96 g, 70%) as 
a white amorphous solid.  
Data for 11. Rf = 0.55 (EtOAc); 1H NMR (CDCl3, 400 MHz) δ 8.72 (brs, 1H, NH), 8.01 (dd, J = 
1.0, 5.6 Hz, 1H, H-C(6)), 7.48 (d, J = 8.1 Hz, H-arom, 2H,), 7.38 (t, J = 9.0 Hz, 4H, H-arom), 
7.18 (m, 3H, H-arom), 6.75 (dd, J = 6.9, 8.7 Hz, 4H, H-arom), 5.83 (dd, J = 1.9, 5.9 Hz, 1H, H-
C(1‘)), 3.72 (m, 6H, 2xOMe), 3.63 (m, 1H, OCH2), 3.50 (m, 1H, OCH2), 3.37 (m, 2H, 2x 
(Me2CH)N), 2.76 (m, 1H, Hb-C(7‘)), 2.62 (m, 1H, Hb-C2‘)), 2.48 (t, J = 6.3 Hz, 2H, CH2CN), 
2.32 (m, 2H, Ha-C(2‘), H-(4‘)), 2.02 (m, 1H, Ha-C(7‘)), 2.02 (s, 3H, CH3), 1.72 (m, 1H, Hb-
C(8‘)), 1.01 (m, 12H, 2x(CH3)2CHN), 0.84 (m, 1H, Ha-C(8‘)); 13C NMR (CDCl3, 100 MHz) δ 
164.29, 164.26 (s, CO), 159.0 (m, 2xC-arom), 150.1 (s, CO), 145.8, 145.7 (s, C-arom), 136.5 (m, 
C-arom), 136.0 (d, C(6)), 131.2, 131.0, 128.8, 127.8, 127.3, 127.2, (6d, 6xC-arom), 117.6, 117.5 
(2s, CN), 113.14, 113.10 (2d, 2xC-arom), 110.22, 110.19 (2s, C(5)), 91.3 (d, C(4‘)), 89.5, 89.3 
(2d, C(1‘)), 89.0, 88.9 (2s), 83.8, 83.7 (2d, J (C,F) = 11.6 Hz and 12.4 Hz C-(3‘)), 83.3, 83.20 
(2d, J (C,F) = 248.0, Hz C(6‘)), 64.5 (m, C(5‘)), 58.0, 57.7 (2td, J (C,P) = 19.5 Hz, OCH2), 55.4, 
55.3 (2q, 2xOMe), 45.9, 45.4 (2td, J (C,P) = 9.7 Hz and 12.9 Hz, C(2‘)), 43.4, 43.3 (2dd, J (C,P) 
= 6.7 Hz, Me2CH), 42.1 (m, C(7‘)), 24.50, 24.45, 24.42, 24.37 (4q, Me2CH), 20.5, 20.4 (2td, 
CH2CN J (C,P) =3.6 Hz, 4.1 Hz), 20.0 (m, C(8‘)), 12.5 (q, CH3); 19F NMR (CDCl3, 376 MHz) δ 
-193.8 (m), -193.6 (m); 31P NMR (CDCl3, 161 MHz): 145.0, 142.9; ESI
+-HRMS m/z calcd for 
C43H50FN4O8PNa [M+Na]
+ 823.3243, found 823.3276. 
(5‘-O-(tert-Butyldimethylsilyl)- 3‘-O-(trimethylsilyl)-2‘-deoxy-3‘,5‘-ethano-6‘-fluoro-5‘,6‘-
methano-β-D-ribofuranosyl)-4-(1H-1,2,4-triazol-1-yl)thymine (12). A suspension of 1,2,4-
triazol (19.81 g, 0.29 mol) in CH3CN was cooled to 0°C and treated consecutively with POCl3 
(2.97 ml, 31.87 mmol) and Et3N (40.9 ml, 293.25 mmol). The resulting mixture was stirred for 50 
min before compound 8 (6.18 g, 12.75 mmol), dissolved in CH3CN (105 mL), was added. After 
completion (TLC control, 3.5 h) the reaction was quenched with sat aq NaHCO3 (200 mL). The 
ice bath was removed and reduced to half of the volume in vacuo. Then EtOAc (200 mL) was 
added and the volume again reduced to one third. After pouring onto H2O/sat aq NaCl 1:1, the 
resulting mixture was extracted with EtOAc. The combined organic phases were dried (MgSO4) 
and evaporated. The crude compound 12 was used directly in the next step without further 
purification. For analytical data a sample was purified by CC (hexane/EtOAc 50:50).  
Data for 12. Rf = 0.35 (hexane/EtOAc 1:1);
 1H NMR (CDCl3, 400 MHz) δ 9.28 (s, 1H, H-C(5´´)), 
8.53 (s, 1H, H-C(6)), 8.11 (s, 1H, H-C(3´´)), 6.18 (t, J = 3.9 Hz, 1H,H-C(1‘)), 4.18 (d, J = 5.6 Hz, 
1H, H-C(4‘)), 2.76 (d, J = 3.9 Hz, 2H, H-C(2‘)), 2.45 (s, 3H, CH3), 2.34 (dd, J = 2.3, 13.9 Hz, 
1H, Hb-C(7‘)), 1.85 (m, 1H, Ha-C(7‘)), 1.44 (ddd, J = 2.3, 7.7, 21.0 Hz, 1H, Hb-C(8‘)), 1.20 (dd, J 
= 7.7, 9.1 Hz, 1H, Ha-C(8‘)), 0.96 (s, 9H, t-Bu), 0.27, 0.22 (2s, 2x3H, 2xCH3), 0.13 (s, 9H, TMS); 
13C NMR (CDCl3, 100 MHz) δ 158.6 (s, C(4)), 154.0 (s, CO), 153.6 (d, C(3´´)), 147.6 (d, C(6)), 
145.2 (d, C(5´´)), 106.0 (s, C(5)), 93.5 (dd, J (C,F) = 3.9 Hz, C(4‘)), 91.6 (d, C(1‘)), 82.3 (d, J 
(C,F) = 12.1 Hz, C(3‘)), 81.3 (d, J (C,F) = 249.3 Hz, C(6‘)), 63.3 (d, J (C,F) = 8.1 Hz, C(5‘)), 
46.4 (t, C(2‘)), 45.0 (td, J (C,F) = 14.7 Hz, C(7‘)), 25.7 (q, t-Bu), 20.2 (td, J (C,F) = 10.0 Hz, 
C(8‘)), 18.0 (s, t-Bu), 16.9 (q, CH3), 2.0 (q, TMS), -3.7 (q, CH3), -3.8 (q, CH3); 19F NMR (CDCl3, 
376 MHz) δ -197.7 (m); ESI+-HRMS m/z calcd for C24H39FN5O4Si2 [M+H]+ 536.2519, found 
536.2503. 
 
(5‘-O-tert-Butyldimethylsilyl)-3‘-O-(trimethylsilyl)-2‘-deoxy-3‘,5‘-ethano-6‘-fluoro-5‘,6‘-
methano-β-D-ribofuranosyl)-5-methyl cytosine (13). To a solution of the crude compound 12 
of the previous step (10 g), dissolved in 1,4-dioxane (110 mL), was added conc NH4OH (110 
mL) and the mixture was stirred for 2 h at rt. The solvent was evaporated and the residue 
dissolved in EtOAc and extracted with H2O and sat NaCl. The aqueous phases were extracted 
with EtOAc and the combined organic layers dried (MgSO4) and evaporated. The residue was 
purified by CC (EtOAc → EtOAc/EtOH 9:1) to yield the title compound 13 (3.70 g, 60%) as 
a white foam.  
Data of 13. Rf = 0.48 (EtOAc/EtOH 9:1); 1H NMR (CDCl3, 400 MHz) δ 7.92 (d, J = 0.7 Hz, 1H, 
H-C(6)), 6.08 (m, 1H, H-C(1‘)), 4.12 (m, 1H, H-C(4‘)), 2.64 (d, J = 3.4 Hz, 2H,H-C(2‘)), 2.28 
(dd, J = 2.0, 13.7 Hz, 1H, Hb-C(7‘)), 1.99 (m, 1H, Ha-C(7‘)), 1.94 (d, J = 0.7 Hz, 3H, CH3), 1.37 
(ddd, J = 2.4, 7.6, 21.0 Hz, 1H, Hb-C(8‘)), 1.17 (dd, J = 7.6, 9.1 Hz, 1H,Ha-C(8‘)), 0.94 (s, 9H, t-
Bu), 0.24, 0.19 (2s, 2x3H, 2xCH3), 0.10 (s, 9H, TMS); 
13C NMR (CDCl3, 100 MHz) δ 166.1 (s, 
C(4)), 156.3 (s, CO), 139.0 (d, C(6)), 101.6 (s, C(5)), 92.9 (dd, J (C,F) = 3.9 Hz, C(4‘)), 90.3 (d, 
C(1‘)), 82.3 (d, J (C,F) = 12.3 Hz, C(3‘)), 81.5 (d, J (C,F) = 249.0 Hz, C(6‘)), 63.3 (d, J (C,F) = 
8.0 Hz, C(5‘)), 46.9 (t, C(2‘)), 44.7 (td, J (C,F) = 14.7 Hz, C(7‘)), 25.7 (q, t-Bu), 20.2 (td, J (C,F) 
= 9.9 Hz, C(8‘)), 18.0 (s, t-Bu), 13.0 (q, CH3), 2.0 (q, TMS), -3.7, -3.8 (2q, 2xCH3); 19F NMR 
(CDCl3, 376 MHz) δ -198.0 (m); ESI+-HRMS m/z calcd for C22H39FN3O4Si2 [M+H]+ 484.2458, 
found 484.2450. 
 N4-Benzoyl-1-(5‘-O-(tert-butyldimethylsilyl)-3‘-O-(trimethylsilyl)-2‘-deoxy-3‘,5‘-ethano-6‘-
fluoro-5‘,6‘-methano-β-D-ribofuranosyl)-5-methyl cytosine (14) and N4-benzoyl-1-(5‘-O-
(tert-butyldimethylsilyl)-2‘-deoxy-3‘,5‘-ethano-6‘-fluoro-5‘,6‘-methano-β-D-ribofuranosyl)-
5-methyl cytosine (15). To a solution of nucleoside 13 (492 mg, 1.01 mmol) and DMAP (25 mg, 
0.20 mmol) in CH3CN (20 mL) was added Bz2O (253 mg, 1.12 mmol) and the mixture was 
stirred for 1.5 h at rt. Then Et3N (0.28 ml, 2.03 mmol) was added and the mixture stirred 
overnight. After evaporation of the solvents the residue was dissolved in EtOAc and washed with 
H2O. The aqueous phase was extracted with EtOAc and the combined organic phases dried 
(MgSO4) and evaporated. The crude product was purified by CC (hexane/EtOAc 95:5 → 
Hex:EtOAc 50:50) to give compound 14 (39%) as awhite foam and compound 15 (54%) as 
a white solid.  
Data for 14. Rf = 0.62 (hexane/EtOAc 1:1); 1H NMR (CDCl3, 400 MHz) δ 13.46 (s, 1H, NH), 
8.32 (d, J = 7.3 Hz, 2H, H-arom), 8.03 (m, 1H, H-C(6)), 7.52 (m, 1H, H-arom), 7.44 (m, 2H, H-
arom), 6.09 (dd, J = 1.1, 6.5 Hz, 1H, H-C(1‘)), 4.11 (d, J = 5.6 Hz, 1H, H-C(4‘)), 2.67 (dd, J = 
6.5, 13.7 Hz, 1H, Hb-C(2‘)), 2.60 (dd, J = 1.1, 13.7 Hz, 1H, Ha-C(2‘)), 2.38 (dd, J = 1.9, 13.7 Hz, 
1H, Hb-C(7‘)), 2.12 (d, J = 0.9 Hz, 3H, CH3), 2.11 (m, 1H, Ha-C(7‘)), 1.43 (ddd, J = 2.4, 7.7, 21.0 
Hz, 1H, Hb-C(8‘)), 1.20 (dd, J = 7.7, 9.0 Hz, 1H, Ha-C(8‘)), 0.97 (s, 9H, t-Bu), 0.26, 0.22 (2s, 
2x3H, 2xCH3), 0.14 (s, 9H, TMS); 
13C NMR (CDCl3, 100 MHz) δ 179.8 (s, C(4)), 160.4 (s, CO), 
147.9 (s, CO), 137.49 (s, C-arom), 137.45 (d, C(6)), 132.4, 130.0, 128.2 (3d, 3xC-arom), 111.4 
(s, C(5)), 93.2 (dd, J (C,F) = 4.0 Hz, C(4‘)), 90.1 (d, C(1‘)), 82.3 (d, J (C,F) = 12.3 Hz, C(3‘)), 
81.4 (d, J (C,F) = 249.5 Hz, C(6‘)), 63.2 (d, J (C,F) = 8.1 Hz, C(5‘)), 47.1 (t, C(2‘)), 44.8 (td, J 
(C,F) = 14.9 Hz, C(7‘)), 25.7 (q, t-Bu), 20.3 (td, J (C,F) = 10.1 Hz, C(8‘)), 18.0 (s, t-Bu), 13.4 (q, 
CH3), 2.0 (q, TMS), -3.7 (q, CH3), -3.8 (q, CH3); 
19F NMR (CDCl3, 376 MHz) δ -197.9 (m); 
ESI+-HRMS m/z calcd for C29H43FN3O5Si2 [M+H]
+ 588.2720, found 588.2714.  
Data for 15. Rf = 0.30 (hexane/EtOAc 1:1); 
1H NMR (CDCl3, 400 MHz) δ 8.29 (m, 2H, H-arom), 
8.07 (d, J = 0.8 Hz, 1H, H-C(6)), 7.48 (m, 4H, H-arom, NH), 6.09 (dd, J = 2.3, 5.6 Hz, 1H, H-
C(1‘)), 4.13 (d, J = 5.5 Hz, 1H, H-C(4‘)), 2.64 (m, 2H, H-C(2‘)), 2.35 (dd, J = 1.6, 13.9 Hz, 1H, 
Hb-C(7‘)), 2.20 (m, 1H, Ha-C(7‘)), 2.12 (d, J = 0.8 Hz, 3H, CH3), 1.46 (ddd, J = 2.4, 7.8, 21.0 Hz, 
1H, Hb-C(8‘)), 1.28 (m, 1H, Ha-C(8‘)), 0.97 (s, 9H, t-Bu), 0.25, 0.21 (2s, 2x3H, 2xCH3); 13C 
NMR (CDCl3, 100 MHz) δ 179.4 (s, C(4)), 160.5 (s, CO), 148.2 (s, CO), 137.9 (d, C(6)), 137.2 
(s, C-arom), 132.6, 123.0, 128.3 (3d, 3xC-arom), 111.5 (s, C(5)), 91.8 (dd, J (C,F) = 3.8 Hz, 
C(4‘)), 90.0 (d, C(1‘)), 81.5 (d, J (C,F) = 249.1 Hz, C(6‘)), 80.7 (d, J (C,F) = 12.0 Hz, C(3‘)), 
63.5 (d, J (C,F) = 8.2 Hz, C(5‘)), 47.9 (t, C(2‘)), 44.8 (td, J (C,F) = 15.8 Hz, C(7‘)), 25.7 (q, t-
Bu), 20.5 (td, J (C,F) = 10.1 Hz, C(8‘)), 18.0 (s, t-Bu), 13.4 (q, CH3), -3.7 (q, CH3), -3.8 (q, CH3); 
19F NMR (CDCl3, 376 MHz) δ -197.6 (m); ESI+-HRMS m/z calcd for C26H35FN3O5Si [M+H]+ 
516.2325, found 516.2328. 
 
N4-Benzoyl-1-(2‘-deoxy-3‘,5‘-ethano-6‘-fluoro-5‘,6‘-methano-β-D-ribofuranosyl)-5-methyl 
cytosine (16). To separate solutions of nucleoside 14 and 15 (1.85 g, 3.15 mmol and 1.24 g, 2.41 
mmol resp.) and pyridine (9.6 mL and 6.0 mL, resp.) in CH2Cl2 (40 mL and 30 mL, resp.) was 
added HF-pyridine (3.3 mL and 2.1 mL, resp.) at 0°C. After stirring for 24 h at rt, silica gel (1g 
per 300 mg starting material) was added and the mixtures stirred for another 15 min. After 
evaporation the adsorbed products were purified by CC (EtOAc) to give the title compound 16 
(1,13 g from 14, 867 mg from 15, 90% together) as white foams.  
Data for 16. Rf = 0.48 (EtOAc); 1H NMR (CD3OD, 400 MHz) δ 8.23 (m, 2H, H-arom), 8.11 (m, 
1H, H-C(6)), 7.58 (m, 1H, H-arom), 7.47 (m, 2H, H-arom), 6.15 (dd, J = 3.1, 7.0 Hz, 1H, H-
C(1‘)), 4.08 (d, J = 5.6 Hz, 1H, H-C(4‘)), 2.65 (dd, J = 7.0, 14.0 Hz, 1H, Hb-(2‘)), 2.53 (dd, J = 
3.1, 14.0 Hz, 1H, Ha-C(2‘)), 2.32 (m, 2H, H-C(7‘)), 2.14 (d, 3H, J = 0.9 Hz, CH3), 1.45 (dd, J = 
7.5, 20.9 Hz, 1H, Hb-C(8‘)), 1.31 (t, J = 7.5 Hz, 1H, Ha-C(8‘)); 13C NMR (CD3OD, 75 MHz) δ 
162.1 (s, C(4)), 148.0 (s, CO), 143.4 (s, CO), 137.7 (d, C(6)), 137.6 (s, C-arom), 133.6, 130.5, 
129.3 (3d, 3xC-arom), 112.0 (s, C(5)), 91.9 (dd, J (C,F) = 3.7 Hz, C(4‘)), 90.2 (d, C(1‘)), 84.3 (d, 
J (C,F) = 248.1 Hz, C(6‘)), 80.8 (d, J (C,F) = 12.0 Hz, C(3‘)), 63.4 (d, J (C,F) = 8.5 Hz, C(5‘)), 
48.2 (t, C(2‘)), 45.2 (td, J (C,F) = 15.5 Hz, C(7‘)), 21.1 (td, J (C,F) = 10.3 Hz, C(8‘)), 13.8 (q, 
CH3); 
19F NMR (CD3OD, 376 MHz) δ -200.4 (m); ESI+-HRMS m/z calcd for C20H21FN3O5 
[M+H]+ 402.1460, found 402.1461.  
 
N4-Benzoyl-1-(5‘-O-((4,4’dimethoxytriphenyl)methyl)-2‘-deoxy-3‘,5‘-ethano-6‘-fluoro-5‘,6‘-
methano-β-D-ribofuranosyl)-5-methyl cytosine (17). To a stirred solution of compound 16 
(606 mg, 1.51 mmol) in pyridine (20 mL) was added DMTrCl (1.54 g, 4.53 mmol) at rt. After 2 
days the mixture was poured onto sat aq NaHCO3 and extraxted with EtOAc. The combined 
organic layers were dried (MgSO4), evaporated and the crude material purified by CC 
(hexane/EtOAc 8:2 → 6:4, +0,2% Et3N) to give the title compound 17 (843 mg, 79%) as 
a  yellowish foam.   
Data for 17. Rf = 0.44 (hexane/EtOAc 1:3); 1H NMR (CDCl3, 400 MHz) δ 13.37 (brs, 1H, NH), 
8.26 (m, 2H, H-arom, H-C(6)), 7.42 (m, 9H, H-arom), 7.20 (m, 4H, H-arom), 6.77 (dd, J = 7.6, 
9.0 Hz, 4H, H-arom), 5.85 (dd, J = 1.5, 6.4 Hz, 1H, H-C(1‘)), 3.73 (s, 3H, OMe), 3.72 (s, 3H, 
OMe), 2.39 (dd, J = 1.5, 14.1 Hz, 1H, Hb-C(2‘)), 2.33 (dd, J = 6.4, 14.1 Hz, 1H, Ha-C(2‘)), 2.22 
(d, J = 0.7 Hz, 3H, CH3), 2.21 (m, 2H, H-C(4‘), Hb-C(7‘)), 2.11 (m, 1H, Ha-C(7‘)), 1.77 (ddd, J = 
2.1, 8.3, 20.4 Hz, 1H, Hb-C(8‘)), 1.56 (brs, 1H, OH), 0.85 (dd, J = 8.3, 9.6 Hz, 1H, Ha-C(8‘)); 13C 
NMR (CDCl3, 100 MHz) δ 181.3 (s, C(4)), 160.4 (s, CO), 159.08, 159.06 (2s, 2xC-arom), 147.9 
(s, CO), 145.9 (s, C-arom), 137.5 (d, C(6)), 137.4, 136.44, 136.37 (3s, 3xC-arom), 132.6, 131.2, 
131.1, 130.0, 128.9, 128.3, 127.9, 127.4, 113.19, 113.15 (10d, 10xC-arom), 111.1 (s, C(5)), 90.9 
(dd, J (C,F) = 4.1 Hz, C(4‘)), 89.4 (d, C(1‘)), 89.0 (s), 83.2 (d, J (C,F) = 248.1 Hz, C(6‘)), 80.8 
(d, J (C,F) = 12.2 Hz, C(3‘)), 64.9 (d, J (C,F) = 7.9 Hz, C(5‘)), 55.4 (q, 2xOMe), 47.9 (t, C(2‘)), 
44.2 (td, J (C,F) = 16.2 Hz, C(7‘)), 20.2 (td, J (C,F) = 9.7 Hz, C(8‘)), 13.6 (q, CH3); 19F NMR 
(CDCl3, 376 MHz) δ -193.5 (m); ESI+-HRMS m/z calcd for C41H39FN3O7 [M+H]+ 704.2767, 
found 704.2771. 
 
N4-Benzoyl-1-(5‘-O-((4,4‘-dimethoxytriphenyl)methyl)- 3‘O-(2-cyanoethoxy)-
diisopropylaminophosphanyl-2‘-deoxy-3‘,5‘-ethano-6‘-fluoro-5‘,6‘-methano-β-D-
ribofuranosyl)-5-methyl cytosine (18).  To a solution of compound 17 (2.37 g, 3.37 mmol) and 
diisopropylethylamine (2.23 mL, 13,47 mmol) in CH3CN (50 mL) was added 2-cyanoethoxy-
diisopropylaminochlorophosphine (1.88 mL, 8.42 mmol). After stirring for 2 h at rt, the mixture 
was diluted with EtOAc and washed with sat aq NaHCO3. The aqueous phases were extracted 
with EtOAc and the combined organic phases dried (MgSO4), evaporated and the crude product 
purified by CC (hexane/EtOAc 1:1, +1% NEt3) to give the title compound 18 (2.78 g, 90 %) as 
a  yellowish foam.  
Data for 18. Rf = 0.71 (hexane/EtOAc 1:3); 1H NMR (CDCl3, 400 MHz) δ 13.39 (brs, 1H, NH), 
8.25 (m, 3H, H-arom, H-C(6)), 7.43 (m, 9H, H-arom), 7.18 (m, 3H, H-arom), 6.76 (m, 4H, H-
arom), 5.88 (d, J = 6.8 Hz, 1H,H-C(1‘)), 3.72 (m, 6H, 2xOMe), 3.62 (m, 1H, OCH2), 3.49 (m, 
1H, OCH2), 3.36 (m, 2H, 2x (Me2CH)N), 2.76 (m, 1H, Hb-C(7‘)), 2.62 (m, 2H, H-C(2‘)), 2.47 
(m, 2H, CH2CN), 2.36 (m, 1H, H-C(4‘)), 2.21 (s, 3H, CH3), 2.01 (m, 1H, Ha-C(7‘)), 1.74 (m, 1H, 
Hb-C(8‘)), 1.01 (m, 12H, 2x(CH3)2CHN), 0.85 (m, 1H, Ha-C(8‘)); 13C NMR (CDCl3, 100 MHz) δ 
179.7 (s, C(4)), 160.4 (s, CO), 159.1, 159.04, 159.02, 159.01 (4s, 4xC-arom), 147.8 (s, CO), 
145.70, 145.65 (2s, C-arom), 137.4 (d, C(6)), 136.43, 136.39 136.32 (3s, 3xC-arom), 132.4, 
131.2, 131.0, 130.0, 128.8, 128.2, 127.9, 127.3, 127.2, (9d, 9xC-arom), 117.5, 117.4 (2s, CN), 
113.2, 113.1 (2d, 2xC-arom), 111.31, 111.27 (2s, C(5)), 91.5 (md, C(4‘)), 90.0, 89.9 (2d, C(1‘)), 
89.03, 88.98 (2s), 83.7 (m, C(3‘)), 83.3, 83.2 (2d, J (C,F) = 248.6 Hz, C(6‘)), 64.63, 64.55 (2d, J 
(C,F) = 3.6 Hz, C(5‘)), 58.0, 57.7 (2td, J (C,P) = 19.4 Hz, OCH2), 55.34, 55.30 (2q, 2xOMe), 
45.7, 45.2 (2td, J (C,P) = 9.7, 12.9 Hz, C(2‘)), 43.4, 43.3 (2dd, J (C,P) = 12.6 Hz, 2xMe2CH), 
42.2, 42.1 (2td, J (C,F) J (C,P) = 10.5, 12.3 Hz, C(7‘)), 24.53, 24.47, 24.40, 24.35 (4q, 
2xMe2CH), 20.4, 20.3 (2td J (C,P) =2.0, 2.7 Hz, CH2CN), 20.0, 19.9 (2td, J (C,F) = 10.2 Hz, 
C(8‘)), 13.5 (q, CH3); 19F NMR (CDCl3, 376 MHz) δ -193.7 (m), -193.5 (m); 31P NMR (CDCl3, 
161 MHz) d 145.1, 143.0; ESI+-HRMS m/z calcd for C50H56FN5O8P [M+H]
+ 904.3845, found 
904.3846. 
 
Oligonucleotide synthesis and purification. Oligonucleotides ON1-10 were synthesized by 
standard solid phase phosphoramidite methodology on the 1.3 μmol scale on a Pharmacia LKB 
Gene Assembler Special DNA Synthesizer using a slightly modified DNA synthesis program. 
Natural phosphoramidites (dT, dC4Bz, dA6Bz, dG2dmf) were coupled as a 0.1 M solution in 
CH3CN, tricyclophosphoramidites as 0.15 M solutions in CH3CN with the exception of 6’F-tc-T, 
6’F-tc-5MeC4Bz and tc-A that were used as 0.15 M solutions in DCE. The coupling step was 90 s 
for natural phosphoramidites and 12 min for tricyclo-phosphoramidites. As coupling reagent, 5-
(ethylthio)-1H-tetrazole (0.25 M in CH3CN) was used. Capping, oxidation and detritylation were 
carried out using standard solutions as described in the manufacturer’s protocol. Deprotection of 
the oligonucleotides after assembly and detachment from solid support was effected by standard 
ammonia treatment (33% aq NH3,16h, 55°C). The crude oligomers were purified by ion-
exchange HPLC using a DNAPAC PA200, 4 x 250 mm analytical column (Dionex). Mobile 
phases A: 25 mM TRIZMA in H2O, pH 8.0. B: 25 mM TRIZMA, 1.25 M NaCl in H2O, pH 8.0. 
or A: 10 mM NaOH in H2O, pH 12.0. B: 10 mM NaOH, 1.5 M NaCl in H2O, pH 12.0, flow 
1ml/min detection at 260 nm. Purified oligonucleotides were desalted over Sep-Pak cartridges, 
quantified at 260 nm using extiction coefficients as determined previously for tricyclo-
nucleosides,31 and analyzed by ESI-- mass spectrometry. Oligonucleotides were then stored at -
18°C. 
UV-melting curves. Absorbances were monitored at 260 nm and the heating rate was set to 
0.5°C/min. A cooling-heating-cooling cycle in the temperature range 20-80°C was applied. Tm 
values were obtained from the derivative curves using the Varian WinUV software. To avoid 
evaporation of the solution, the sample solutions were covered with a layer of 
dimethylpolysiloxane. All measurements were carried out in 150 mM NaCl, 10 mM Na-
phosphate, pH 7.0 with duplex concentration of 2 μM. 
CD-spectroscopy. CD spectra were recorded using the same buffer conditions and 
oligonucleotide concentrations as for UV melting curves. All CD spectra were collected at 20°C 
between 210 to 320 nm at a 50 nm/min rate and were baseline-corrected against buffer. The 
reported spectra correspond to the average of at least three scans. 
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